Xuemei Wang

17.6k total citations · 1 hit paper
252 papers, 10.4k citations indexed

About

Xuemei Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology. According to data from OpenAlex, Xuemei Wang has authored 252 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Pulmonary and Respiratory Medicine, 59 papers in Oncology and 58 papers in Hematology. Recurrent topics in Xuemei Wang's work include Acute Myeloid Leukemia Research (41 papers), Prostate Cancer Treatment and Research (39 papers) and Gastric Cancer Management and Outcomes (27 papers). Xuemei Wang is often cited by papers focused on Acute Myeloid Leukemia Research (41 papers), Prostate Cancer Treatment and Research (39 papers) and Gastric Cancer Management and Outcomes (27 papers). Xuemei Wang collaborates with scholars based in United States, China and Canada. Xuemei Wang's co-authors include Peter F. Thall, Kim‐Anh Do, Louis L. Pisters, Andrew K. Lee, Dan Leibovici, Philippe E. Spiess, Hagop M. Kantarjian, Richard E. Champlin, Kim‐Anh Do and Marcos de Lima and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Biotechnology.

In The Last Decade

Xuemei Wang

243 papers receiving 10.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy

2006 1.0k citations Xuemei Wang et al. Cancer profile →

Peers

Countries citing papers authored by Xuemei Wang

Since Specialization

Citations

This map shows the geographic impact of Xuemei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuemei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuemei Wang more than expected).

Fields of papers citing papers by Xuemei Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xuemei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuemei Wang. The network helps show where Xuemei Wang may publish in the future.

Co-authorship network of co-authors of Xuemei Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Xuemei Wang. A scholar is included among the top collaborators of Xuemei Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuemei Wang. Xuemei Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study 2024 ·Cancers ·Matheus Sewastjanow‐Silva, Lianchun Xiao, Graciela M. Nogueras‐González, Xuemei Wang, Wayne L. Hofstetter, Stephen G. Swisher, Reza J. Mehran, Boris Sepesi, Manoop S. Bhutani, Brian Weston, Emmanuel Coronel, Rebecca Waters, Jane E. Rogers, (unknown), L. R. Lyons, Norelle R. Reilly, James C. Yao, Jaffer A. Ajani, Mariela Blum Murphy	1
2	Loss of ACTL7A causes small head sperm by defective acrosome-acroplaxome-manchette complex 2023 ·Reproductive Biology and Endocrinology ·Yini Zhang, Jianan Tang, Xuemei Wang, (unknown), (unknown), (unknown), Xinyue Yang, Huijuan Shi, Xiaoxi Sun, Aijie Xin	9
3	Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission 2023 ·Blood ·Elias Jabbour, Fadi Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey L. Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney D. DiNardo, Lucia Masárová, Tapan M. Kadia, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian	25
4	Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones 2022 ·Prostate Cancer and Prostatic Diseases ·(unknown), Andrew W. Hahn, (unknown), Miao Zhang, Anh Hoang, Jian H. Song, Jingjing Liu, Feng Wang, Hirak S. Basu, (unknown), Xuemei Wang, Daniel E. Frigo, Sue-Hwa Lin, Theocharis Panaretakis, Jianhua Zhang, Nora M. Navone, Patricia Troncoso, Christopher J. Logothetis, Mark Titus	3
5	Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia 2022 ·American Journal of Hematology ·Jayastu Senapati, Mahran Shoukier, Guillermo Garcia‐Manero, Xuemei Wang, Keyur P. Patel, Tapan M. Kadia, Farhad Ravandi, Naveen Pemmaraju, Maro Ohanian, Naval Daver, Courtney D. DiNardo, Yesid Alvarado, (unknown), Gautam Borthakur	15
6	Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients 2022 ·American Journal of Hematology ·Gautam Borthakur, Farhad Ravandi, Keyur P. Patel, Xuemei Wang, Tapan M. Kadia, Courtney D. DiNardo, Guillermo Garcia‐Manero, Naveen Pemmaraju, Elias Jabbour, Koichi Takahashi, Maro Ohanian, Naval Daver, Yesid Alvarado, Mark Brandt, Sherry Pierce, Hagop M. Kantarjian	20
7	Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10⁻⁴ and higher 2022 ·American Journal of Hematology ·Elias Jabbour, Nicholas J. Short, Nitin Jain, (unknown), Jeffrey L. Jorgensen, Sa Wang, Xuemei Wang, Maro Ohanian, Yesid Alvarado, Tapan M. Kadia, Koji Sasaki, Rebecca Garris, Guillermo Garcia‐Manero, Farhad Ravandi, Hagop M. Kantarjian	23
8	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy 2022 ·Blood Cancer Journal ·Sangeetha Venugopal, Koichi Takahashi, Naval Daver, Abhishek Maiti, Gautam Borthakur, Sanam Loghavi, Nicholas J. Short, Maro Ohanian, Lucia Masárová, Ghayas C. Issa, Xuemei Wang, (unknown), Musa Yılmaz, Tapan M. Kadia, Michael Andreeff, Farhad Ravandi, Marina Konopleva, Hagop M. Kantarjian, Courtney D. DiNardo	63
9	Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary 2021 ·Clinical Cancer Research ·Kanwal Raghav, Hyunsoo Hwang, Alexandre A. Jácome, (unknown), (unknown), Ryan Huey, (unknown), (unknown), Brandon G. Smaglo, Aurelio Matamoros, Jeannelyn S. Estrella, (unknown), Michael J. Overman, Xuemei Wang, F. Anthony Greco, Jonathan M. Loree, Gauri R. Varadhachary	26
10	Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia 2021 ·British Journal of Haematology ·(unknown), (unknown), Shilpa Paul, Xuemei Wang, Koji Sasaki, Philip A. Thompson, Jan A. Burger, Alessandra Ferrajoli, Zeev Estrov, Susan O’Brien, Michael J. Keating, William G. Wierda, Nitin Jain	2
11	Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer 2021 ·European Journal of Cancer ·(unknown), (unknown), (unknown), John W. Davis, Amado J. Zurita, Xuemei Wang, Shi‐Ming Tu, Brian F. Chapin, Ana M. Aparicio, Paul G. Corn, Jennifer Wang, Sumit K. Subudhi, John C. Araujo, John Papadopoulos, (unknown), (unknown), Christopher J. Logothetis, Eleni Efstathiou	12
12	Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer 2019 ·Clinical Cancer Research ·Jennifer B. Goldstein, Li Zhao, Xuemei Wang, (unknown), Michael J. Overman, Milind Javle, Rachna T. Shroff, Gauri R. Varadhachary, Robert A. Wolff, Florencia McAllister, P. Andrew Futreal, David R. Fogelman	29
13	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia 2019 ·Cancer ·Kamal Chamoun, Hagop M. Kantarjian, Xuemei Wang, Kiran Naqvi, Fleur M. Aung, Guillermo Garcia‐Manero, Gautam Borthakur, Elias Jabbour, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Nitin Jain, Marina Konopleva, Jörge E. Cortes, Farhad Ravandi, Musa Yılmaz	18
14	Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF) 2017 ·Blood ·Prithviraj Bose, Naveen Pemmaraju, Kurt Schroeder, Alessandra Ferrajoli, Elias Jabbour, Naval Daver, Courtney D. DiNardo, Yesid Alvarado, Musa Yılmaz, (unknown), Wei Qiao, Xuemei Wang, Aurelio Matamoros, Lingsha Zhou, Sherry Pierce, Hagop M. Kantarjian, Srđan Verstovšek	2
15	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics 2016 ·Clinical Cancer Research ·Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George A. Călin, Susan O’Brien, Stefan Faderl, Xuemei Wang, William G. Wierda, Katayoun Rezvani, James M. Reuben, Jan A. Burger, Michael J. Keating, Alessandra Ferrajoli	23
16	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers 2015 ·Clinical Cancer Research ·Ana M. Aparicio, Li Shen, Elsa Li Ning Tapia, Jing‐Fang Lu, Hsiang-Chun Chen, Jiexin Zhang, Guanglin Wu, Xuemei Wang, Patricia Troncoso, Paul G. Corn, Timothy C. Thompson, Bradley M. Broom, Keith Baggerly, Sankar N. Maity, Christopher J. Logothetis	192
17	PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors 2011 ·Molecular Cancer Therapeutics ·Filip Jankú, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Xuemei Wang, Rajyalakshmi Luthra, David S. Hong, Aung Naing, Gerald S. Falchook, John W. Moroney, Sarina A. Piha‐Paul, Jennifer J. Wheler, Stacy Moulder, Siqing Fu, Razelle Kurzrock	289
18	Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation 2011 ·Blood ·Stefan O. Ciurea, Peter F. Thall, Xuemei Wang, Sa A. Wang, (unknown), Pedro Cano, Fleur M. Aung, Gabriela Rondón, Jeffrey J. Molldrem, Martin Körbling, Elizabeth J. Shpall, Marcos de Lima, Richard E. Champlin, Marcelo Fernández-Viña	148
19	Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment 2010 ·Clinical Cancer Research ·Ignacio Garrido‐Laguna, Filip Jankú, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, (unknown), Xuemei Wang, Merrill S. Kies, Razelle Kurzrock	14
20	Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma 2009 ·Journal of Clinical Oncology ·Eric Jonasch, Christopher G. Wood, Surena F. Matin, Shi‐Ming Tu, Lance C. Pagliaro, Paul G. Corn, Ana M. Aparicio, Pheroze Tamboli, Randall E. Millikan, Xuemei Wang, John C. Araujo, Wadih Arap, Nizar M. Tannir	136

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact